$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000154422716000008 Filed on February 26, 2016

Income Statement

Concept	2016 Q1	2014 Q4	2013 Q1
Revenue	$146.0K	$0.00	$0.00
YoY Change	873.33%
Cost Of Revenue	$1.176M
YoY Change	3260.0%
Gross Profit	-$1.030M
YoY Change	5050.0%
Gross Profit Margin	-705.48%
Selling, General & Admin	$14.45M	$11.02M	$2.500M
YoY Change	30.85%	195.44%	23.76%
% of Gross Profit
Research & Development	$5.955M	$7.270M	$2.680M
YoY Change	3.62%	-0.14%	183.3%
% of Gross Profit
Depreciation & Amortization	$504.0K	$190.0K	$47.00K
YoY Change	122.03%	216.67%
% of Gross Profit
Operating Expenses	$21.59M	$18.29M	$5.175M
YoY Change	28.27%	66.12%	74.48%
Operating Profit	-$21.44M		-$5.175M
YoY Change	27.51%		74.48%
Interest Expense	-$220.0K	-$690.0K	$20.00K
YoY Change	-48.84%	-7000.0%
% of Operating Profit
Other Income/Expense, Net	-$27.00K	$80.00K
YoY Change	-179.41%
Pretax Income	-$21.68M	-$18.89M	-$5.160M
YoY Change	26.02%	71.73%	73.74%
Income Tax	$75.00K		$0.00
% Of Pretax Income
Net Earnings	-$21.76M	-$18.89M	-$5.157M
YoY Change	26.46%	71.73%	73.87%
Net Earnings / Revenue	-14902.74%
Basic Earnings Per Share
Diluted Earnings Per Share	-$181.30	-$171.70	-$86.00
COMMON SHARES
Basic Shares Outstanding	27.30M shares		14.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2014 Q4	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$110.1M	$60.20M	$59.70M
YoY Change	-34.97%	35.59%	55.87%
Cash & Equivalents	$20.48M	$6.414M	$43.19M
Short-Term Investments	$89.60M	$53.80M	$16.50M
Other Short-Term Assets	$2.600M	$1.600M	$500.0K
YoY Change	30.0%	128.57%	400.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$112.7M	$61.88M	$60.18M
YoY Change	-34.19%	37.27%	56.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.667M	$3.367M	$895.0K
YoY Change	106.36%	282.61%	123.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$215.0K	$0.00
YoY Change	7.5%	-100.0%
Other Assets	$400.0K	$130.0K	$88.00K
YoY Change	300.0%	30.0%
Total Long-Term Assets	$9.321M	$3.694M	$983.0K
YoY Change	107.13%	49.68%	145.75%
TOTAL ASSETS
Total Short-Term Assets	$112.7M	$61.88M	$60.18M
Total Long-Term Assets	$9.321M	$3.694M	$983.0K
Total Assets	$122.1M	$65.57M	$61.17M
YoY Change	-30.57%	37.92%	57.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.218M	$2.520M	$948.0K
YoY Change	68.72%	52.36%	-36.8%
Accrued Expenses	$7.600M	$7.654M	$1.146M
YoY Change	85.37%	85.78%	4.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.81M	$10.17M	$2.094M
YoY Change	78.89%	76.2%	-19.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.400M	$73.00K	$11.00K
YoY Change	1300.0%	4.29%	-89.0%
Total Long-Term Liabilities	$1.400M	$73.00K	$11.00K
YoY Change	1300.0%	4.29%	-89.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.81M	$10.17M	$2.094M
Total Long-Term Liabilities	$1.400M	$73.00K	$11.00K
Total Liabilities	$13.22M	$10.25M	$2.105M
YoY Change	97.25%	75.34%	-22.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$189.7M	-$94.70M	-$21.29M
YoY Change		109.61%
Common Stock	$27.00K	$24.00K	$18.00K
YoY Change		33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$108.8M	$55.33M	$59.06M
YoY Change
Total Liabilities & Shareholders Equity	$122.1M	$65.57M	$61.17M
YoY Change	-30.57%	37.92%	57.65%

Cashflow Statement

Concept	2016 Q1	2014 Q4	2013 Q1
OPERATING ACTIVITIES
Net Income	-$21.76M	-$18.89M	-$5.157M
YoY Change	26.46%	71.73%	73.87%
Depreciation, Depletion And Amortization	$504.0K	$190.0K	$47.00K
YoY Change	122.03%	216.67%
Cash From Operating Activities	-$15.41M	-$10.53M	-$4.060M
YoY Change	7.06%	125.0%	395.12%
INVESTING ACTIVITIES
Capital Expenditures	$370.0K	$1.330M	$184.0K
YoY Change	-4.88%	533.33%	-57.31%
Acquisitions
YoY Change
Other Investing Activities	-$6.970M	$5.990M	$0.00
YoY Change	-138.13%	204.06%
Cash From Investing Activities	-$7.336M	$4.650M	-$180.0K
YoY Change	-141.0%	164.2%	-58.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$32.70M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	160.0K	32.65M
YoY Change	-100.0%	-300.0%	-6.69%
NET CHANGE
Cash From Operating Activities	-$15.41M	-10.53M	-4.060M
Cash From Investing Activities	-$7.336M	4.650M	-180.0K
Cash From Financing Activities	$0.00	160.0K	32.65M
Net Change In Cash	-$22.75M	-5.720M	28.41M
YoY Change	-117.73%	90.67%	-15.8%
FREE CASH FLOW
Cash From Operating Activities	-$15.41M	-$10.53M	-$4.060M
Capital Expenditures	$370.0K	$1.330M	$184.0K
Free Cash Flow	-$15.78M	-$11.86M	-$4.244M
YoY Change	6.74%	142.54%	239.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	727200000	USD
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27300198	shares
CY2015	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	829000	USD
CY2015Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1540000	USD
CY2014Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	793000	USD
CY2015Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	813000	USD
CY2014Q4	ovas	Collaborative Arrangements Technology Access Fee Payable In Cash Upon Specified Passage Of Time CollaborativeArrangementsTechnologyAccessFeePayableInCashUponSpecifiedPassageOfTime	2500000	USD
CY2014Q4	ovas	Common Stock Shares Reserved For Potential Conversion Of Restricted Stock Units CommonStockSharesReservedForPotentialConversionOfRestrictedStockUnits	54078	shares
CY2015Q4	ovas	Common Stock Shares Reserved For Potential Conversion Of Restricted Stock Units CommonStockSharesReservedForPotentialConversionOfRestrictedStockUnits	100451	shares
CY2014Q4	ovas	Common Stock Shares Reserved For Potential Conversion Of Stock Options CommonStockSharesReservedForPotentialConversionOfStockOptions	3628628	shares
CY2015Q4	ovas	Common Stock Shares Reserved For Potential Conversion Of Stock Options CommonStockSharesReservedForPotentialConversionOfStockOptions	4650114	shares
CY2014Q4	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	2567000	USD
CY2015Q4	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	734000	USD
CY2015	ovas	Increase Decreasein Tax Credit Carryforward IncreaseDecreaseinTaxCreditCarryforward	500000	USD
CY2013	ovas	Issuance Of Common Stock For Technology Access Fee IssuanceOfCommonStockForTechnologyAccessFee	2500000	USD
CY2014	ovas	Issuance Of Common Stock For Technology Access Fee IssuanceOfCommonStockForTechnologyAccessFee	0	USD
CY2015	ovas	Issuance Of Common Stock For Technology Access Fee IssuanceOfCommonStockForTechnologyAccessFee	165000	USD
CY2015Q1	ovas	Number Of Shares Issued Upon Full Exercise Of Options Granted To Underwriters NumberOfSharesIssuedUponFullExerciseOfOptionsGrantedToUnderwriters	345000	shares
CY2014Q1	ovas	Number Of Shares Represents Partial Exercise Of Overallotment Option Granted To Underwriters NumberOfSharesRepresentsPartialExerciseOfOverallotmentOptionGrantedToUnderwriters	518630	shares
CY2015Q4	ovas	Numberof Treatments NumberofTreatments	1	treatment
CY2015Q4	ovas	Operating Leases Improvement Allowance OperatingLeasesImprovementAllowance	1200000	USD
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
CY2013	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	0	USD
CY2014	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	-21000	USD
CY2015	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	1323000	USD
CY2013Q1	ovas	Stock Issued Shares Private Placement Basis StockIssuedSharesPrivatePlacementBasis	3888880	shares
CY2013	ovas	Stock Issued Value Private Placement Basis StockIssuedValuePrivatePlacementBasis	32656000	USD
CY2013	ovas	Stock Issued Value Under Collaborative Arrangement StockIssuedValueUnderCollaborativeArrangement	2500000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2520000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3352000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7654000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7891000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	7654000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	7566000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1138000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2420000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-170000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150025000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	294910000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5094000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12407000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19337000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	586000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	871000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1116000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3496000	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4012000	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4751000	shares
CY2013	us-gaap	Asset Impairment Charges AssetImpairmentCharges	364000	USD
CY2014	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2015	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2014Q4	us-gaap	Assets Assets	65572000	USD
CY2015Q4	us-gaap	Assets Assets	138613000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	61878000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	129861000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	60231000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	126662000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	28000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	170000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	60257000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	126832000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	44200000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	81400000	USD
CY2014Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	32	security
CY2015Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	43	security
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14776000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18078000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6414000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43224000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	126700000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36909000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	49211000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24413666	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27296747	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24084637	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27296747	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29028000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49556000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73363000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	16000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-36000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-144000	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2015	us-gaap	Cost Of Revenue CostOfRevenue	2249000	USD
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	54000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	75000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	21000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2536000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3109000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26133000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36127000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	305000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	553000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1689000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2296000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5591000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6472000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	655000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	654000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36909000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	231000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	450000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1286000	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49211000	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.80
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.19
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.70
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0010
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4050
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3886
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1682
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0159
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.1425
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0092
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0027
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0815
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0528
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0528
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0523
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0017
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0031
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0094
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0231
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0175
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0083
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2753000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2237000	USD
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	34900000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M5D
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29044000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49520000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73144000	USD
CY2013	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2014	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1583000	USD
CY2015	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1561000	USD
CY2013	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	0	USD
CY2014	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-1583000	USD
CY2015	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-1561000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-721000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2317000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-171000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11243000	USD
CY2013	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3302000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50286000	USD
CY2014	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-11664000	USD
CY2015	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	36810000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32414000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51712000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125386000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-29044000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-49520000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11018000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32788000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38290000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18094000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30588000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2972000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2301000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	752000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	76000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	997000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1113000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-5000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	109000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	681000	USD
CY2015Q3	us-gaap	Inventory Write Down InventoryWriteDown	400000	USD
CY2015Q4	us-gaap	Inventory Write Down InventoryWriteDown	500000	USD
CY2013	us-gaap	Investment Income Net InvestmentIncomeNet	90000	USD
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	-126000	USD
CY2015	us-gaap	Investment Income Net InvestmentIncomeNet	436000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	10247000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	11763000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65572000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138613000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10174000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-73219000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29044000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49520000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-73219000	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	133000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1003000	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	1500000	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	0	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	0	USD
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2013	us-gaap	Operating Expenses OperatingExpenses	29134000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	47933000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015	us-gaap	Operating Expenses OperatingExpenses	72276000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-29134000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-47933000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-71999000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4777000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	973000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	924000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	985000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	960000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	935000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	712000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2242000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-36000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-144000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	73000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	520000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	122000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	USD
CY2013	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	0	USD
CY2014	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
CY2015	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
CY2015	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	719000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2804000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5229000	USD
CY2013	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15974000	USD
CY2014	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	57603000	USD
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	95225000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1647000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3002000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32700000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51733000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124063000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51700000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124100000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32414000	USD
CY2013	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	5670000	USD
CY2014	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	20797000	USD
CY2015	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	53528000	USD
CY2013	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2014	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	8431000	USD
CY2015	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	10817000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.20
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	564866	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1795100	shares
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4505000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10733000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3367000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8313000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15802000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21784000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18433000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	197000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	197000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2013	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-285000	USD
CY2014	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1125000	USD
CY2015	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-117000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94698000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167917000	USD
CY2013	us-gaap	Revenues Revenues	0	USD
CY2014	us-gaap	Revenues Revenues	0	USD
CY2015	us-gaap	Revenues Revenues	277000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13332000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26149000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51594000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	5094000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	12407000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	19337000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1461283	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	102355000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2970000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3628628	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4650114	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.01
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.49
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2759000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3948127	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	20.93
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.77
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.60
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.21
CY2013Q1	us-gaap	Share Price SharePrice	9.00
CY2014Q1	us-gaap	Share Price SharePrice	10.00
CY2015Q1	us-gaap	Share Price SharePrice	50.00
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2058000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M10D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M12D
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	53817000	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	83438000	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5518630	shares
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2645000	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	208748	shares
CY2015	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	165000	USD
CY2014	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	51733000	USD
CY2015	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	124063000	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2000	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	163000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1440000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	30721000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	41701000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	55325000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	126850000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19200000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12300000	USD
CY2015	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.50
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16160000	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22647000	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27085000	shares
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no significant off-balance sheet risk.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and short-term investments are the only financial instruments we have that are subject to concentration of credit risk. Cash and cash equivalents are primarily maintained with two major financial institutions in the United States. Deposits at banks may exceed the insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. Short-term investments consist of investment grade corporate debt securities. Our investment policy, which has been approved by our board of directors, limits the amount we may invest in any one issuer of investments, thereby reducing credit risk concentrations.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-16-000008-index-headers.html	Edgar Link	pending
0001544227-16-000008-index.html	Edgar Link	pending
0001544227-16-000008.txt	Edgar Link	pending
0001544227-16-000008-xbrl.zip	Edgar Link	pending
agecharta03.jpg	Edgar Link	pending
exhibit1029.htm	Edgar Link	pending
exhibit1029image1.gif	Edgar Link	pending
exhibit1030.htm	Edgar Link	pending
exhibit1030image1.gif	Edgar Link	pending
exhibit1031.htm	Edgar Link	pending
exhibit211.htm	Edgar Link	pending
exhibit231.htm	Edgar Link	pending
figure1.jpg	Edgar Link	pending
figure2.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20151231.xml	Edgar Link	completed
ovas-20151231.xsd	Edgar Link	pending
ovas-20151231x10k.htm	Edgar Link	pending
ovas-20151231xex311.htm	Edgar Link	pending
ovas-20151231xex312.htm	Edgar Link	pending
ovas-20151231xex321.htm	Edgar Link	pending
ovas-20151231xex322.htm	Edgar Link	pending
ovas-20151231_cal.xml	Edgar Link	unprocessable
ovas-20151231_def.xml	Edgar Link	unprocessable
ovas-20151231_lab.xml	Edgar Link	unprocessable
ovas-20151231_pre.xml	Edgar Link	unprocessable
ovas-201512_chartx51709.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2016 Q1 Form 10-K Financial Statement

#000154422716000008 Filed on February 26, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2016 Q1 Form 10-K Financial Statement

#000154422716000008 Filed on February 26, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst